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Mucin glycoproteins play an important role in protecting the gut epithe-
lium by keeping gut microbes from direct contact with the gut epithelium
while allowing for diffusion of small molecules from the lumen to the
epithelium. The mucin glycocalyx can be degraded by gut bacteria such as
Bacteroides and Akkermansia, but other bacteria, such as Bifidobac-
terium longum subsp. Infantis, cannot consume mucin glycans. Untargeted
mass spectrometry profiles were compared to microbiome profiles to assess
how different gut microbiomes affect colonic mucin degradation. Samples
obtained from nine infants colonized by Bifidobacterium infantis EVC001
and from 10 infants colonized by higher levels of mucolytic taxa (controls),
including Bacteroides, were compared. Previously performed untargeted
nano-high-performance liquid chromatography-chip/time-of-flight mass
spectrometry was used to detect and quantify glycans originating from
colonic mucin. Colonic mucin-derived O-glycans from control infants com-
posed 37.68% ( 3.14% SD) of the total glycan structure pool, whereas
colonic mucin-derived O-glycans made up of only 1.78% ( 0.038% SD)
of the total in B. infantis EVC001 samples. The relative abundance of these
colonic mucin-derived O-glycans in the total glycan pool was higher among
control, 26.98% ( 8.48% SD), relative to B. infantis-colonized infants,
1.68% ( 1.12% SD). Key taxa, such as Bacteroidaceae, were significantly
and positively correlated with the abundance of these structures, while Bifi-
dobacteriaceae were significantly and negatively associated with these struc-
tures. These results suggest that colonization of infants by B. infantis may
diminish colonic glycan degradation and help maintain barrier function in
the gastrointestinal tract of infants.
Mucins are highly glycosylated O-linked glycoproteins
secreted by exocrine glands and mucosa. They contain
a wide variety of glycan structures, which make up
80% of the glycoprotein mass. These glycans attach to
the polypeptide backbone via serine or threonine
residues with N-acetylgalactosamine. Eight O-glycan
cores have been identified [1]. Among these cores, core
1-, 2-, 3-, and 4-derived glycans are predominantly
found in intestinal mucins. Specifically, core 1 (Galb1–
3GalNAca1-Ser/Thr) and core 2 (Galb1,3
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(GlcNAcb1,6)GalNAca1-Ser/Thr) structures are found
in gastric and duodenal mucins, whereas colonic mucins
contain predominantly core 3, 4 (GlcNAcb1,6
(GlcNAcb1,3) GalNAcaSer/Thr) elongated structures
[2,3]. Mucin degradation by mucolytic taxa like Bac-
teroides is achieved with a wide variety of enzymes, such
as proteases, sulfatases, fucosidases, neuraminidases, b-
galactosidases, a-N-acetylgalactosaminidases, a-N-acet-
ylglucosaminidases, and exo/endo-b-N-acetyl-glucosami-
nidases [4]. Although the presence of mucin-consuming
taxa is associated with increased mucin production, it is
unclear whether this is a beneficial trait as the break-
down of the mucin barrier is often associated with nega-
tive impacts to the underlying gut epithelium [5], and its
loss can be a pathway to infection [6], loss of gut epithe-
lial barrier function [7], or spontaneous inflammation
resembling colitis [8]. Further, mucin degradation pro-
vides a niche that fosters taxa whose cytotoxic products
can lead to colon cancer [9].
Human milk contains structurally analogous car-
bohydrates in the form of N-linked and O-linked
glycoproteins and glycolipids [10] as well as free gly-
cans, known as human milk oligosaccharides
(HMOs) [11]. Several gut bacteria found in breastfed
infants are able to release and consume mucin gly-
cans (e.g., Bacteroides), and while some species of
Bifidobacterium (e.g., B. bifidum) are able to grow on
mucin as a sole carbon source, others can not (e.g.,
Bifidobacterium infantis) [12]. Interestingly, the taxa
that consume both mucin glycans and HMOs appear
to use the same glycolytic capacities and regulatory
networks to consume these structures, whereas spe-
cialized taxa consume HMOs in unique pathways,
and appear to only express these genes in response
to a limited number of carbohydrates [13–15]. Thus,
adaptation to these two structurally similar carbon
sources appears to be highly specific among different
infant gut-associated bifidobacteria. If this is true,
then the role of mucolytic taxa in the infant gut is
unclear. Further, to what extent is mucus degraded
in the infant gut and which taxa are responsible? To
begin to address these questions, a library of known
colonic mucin-derived O-glycans was compiled and
used to query untargeted mass spectra of fecal sam-
ples from infants from a previous study [16,17]. We
hypothesized that the previously demonstrated modi-
fication of the gut microbiome resulted in the modu-
lation of mucin degradation by gut microbes. A
second part of the hypothesis was that colonization
with B. infantis, which does not degrade mucin, and
the subsequent reduction in mucolytic taxa would
diminish mucin degradation, as measured by the
abundance of freed colonic mucin-derived O-glycans
in the infant’s stool.
Materials and methods
Fecal sample collection and analysis
To examine the effect of Bifidobacterium longum subsp.
infantis (B. infantis) EVC001 colonization on gut mucin
degradation at day 29 postnatal, fecal samples were col-
lected from healthy, breastfed infants fed 1.8 9 1010 CFU
per day B. longum subsp. infantis EVC001 from Day 7
postnatal to Day 29 postnatal (n = 9) and healthy breastfed
infants who were not fed B. longum subsp. infantis EVC001
(n = 10). These samples were randomly selected from the
larger study population for additional analysis using untar-
geted mass spectrometry data that had been collected ini-
tially for the study of human milk glycans found in the
infant’s feces. The initial clinical study was a partially ran-
domized study, and subject populations, as well as ethical
approval for sample collection, were previously noted [16].
Demographics describing the randomly selected subset of
the total population examined in this analysis is presented
in Table S1.
The microbiome composition of these samples was also
previously determined. These data are publicly deposited in
the NCBI SRA (PRJNA390646) and were analyzed using
QIIME 1.9.1 [18] as previously described [17]. Briefly,
paired-end sequencing of the V4 region of the 16S rRNA
gene was performed on an Illumina MiSeq at the University
of California Davis Genome Center (Davis, CA). Open-
reference operational taxonomic unit (OTU) picking was
completed using UCLUST at 97% identity, and low-abun-
dance OTUs were removed as recommended [19]. Across the
full data set, there was a mean of 9216 reads (SD  4505
reads) per sample and samples with at least than 2779 reads
were included for analysis. Here, 19 samples (n = 9, 10)
matching paired mass spectrometry data were selected from
this overall population and analyzed in the context of the
untargeted spectra as described below.
Analysis of spectra obtained with Nano-high-
performance liquid chromatography-chip/time-of-
flight mass spectrometry (nano-LC-MS)
Oligosaccharide (OS) isolation and purification from these
fecal samples were performed previously and reported by
Frese et al. [17]. The structures of human colonic mucin
O-glycans were characterized by analysis on a nano-
HPLC-Chip-TOF mass spectrometer using the methods
described by Davis et al. [20], and this approach was
previously reported for these samples where the concen-
tration of structurally similar HMOs was determined [17].
Briefly, the high-performance liquid chromatography
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(HPLC) system used was an Agilent 1200 series unit with
a microfluidic chip, which was coupled to an Agilent
6220 series time of flight (TOF) mass spectrometer via
chip cube interface. The capillary pump on the chro-
matography unit loaded the sample onto the 40-nL
enrichment column at a flow rate of 4.0 lLmin1 with a
1 lL injection volume. A nano pump was used for ana-
lyte separation on the analytical column, which was
75 9 43 mm and packed with porous graphitized carbon.
Separation was accomplished using a binary gradient of
aqueous solvent A [3% acetonitrile (ACN)/water (v/v) in
0.1% formic acid (FA)] and organic solvent B [90%
ACN/water (v/v) in 0.1% FA] using a method developed
for HMO separation (7, 8). The sample was introduced
into the TOF mass spectrometer via electrospray ioniza-
tion, which was tuned and calibrated using a dual nebu-
lizer electrospray source with calibrant ions ranging from
m/z 118.086 to 2721.895, and data were collected in the
positive mode. These untargeted spectra were analyzed in
the present study as described below.
Glycan data analysis
The untargeted mass spectra were collected (as above) and
analyzed using Agilent MassHunter Workstation Data
Acquisition version B.02.01 on the nano-HPLC-Chip-TOF.
The ‘Find Compounds by Molecular Feature’ function of
the software was used to identify mucin glycan species
within 20 ppm of theoretical masses. Compound abun-
dances were expressed as volume in ion counts that corre-
sponded to absolute abundances of the compounds in each
sample. 1HexNAc-1NeuAc, 1HexNAc-1Hex-NeuAc, 2Hex-
NAc-1NeuAc, 2HexNAc-1Hex-1Fuc, 2HexNAc-1Hex-
1NeuAc, 2HexNAc-1Hex-2Fuc, 3HexNAc-1Hex-1Fuc, 2He
xNAc-1Hex-1Fuc-1NeuAc, 2HexNAc-1Hex-1Fuc-2Neu
Ac, 3HexNAc-1Hex-2NeuAc and 3HexNAc-1Hex-2Fuc-
1NeuAc were monitored as they are discriminatively
human colonic mucin O-glycans [21].
Statistical analysis
Multiple t-tests, corrected using the Holm–Sidak method for
multiple comparisons, were carried out in Graph Pad Prism
7 (GRAPHPAD Software, La Jolla, CA, USA). Wilcoxon rank-
sum test was used for single comparisons. P values, or
adjusted P values, of 0.05 or less in comparisons were consid-
ered significantly different. Differences in bacterial commu-
nity composition and colonic mucin-derived O-glycans were
calculated in several, complementary ways. First, a weighted
UniFrac distance matrix [22] was used to visualize differ-
ences in community composition according to treatment
group using principal coordinate analysis (PCoA). Second, a
Bray–Curtis dissimilarity index between all colonic mucin-
derived O-glycan species was visualized via PCoA. To evalu-
ate the effect size of EVC001 colonization, both weighted
UniFrac and Bray–Curtis dissimilarity matrices were tested
via Permanova multivariate comparisons with 999 permuta-
tions and FDR-corrected P-values. Mantel tests were used to
assess significant relationships between the phylogenetic dis-
tance of the bacterial communities and the colonic mucin-
derived O-glycan abundance. Colonic mucin-derived O-gly-
can abundance was transformed to dissimilarity matrices
using Euclidean distance, while phylogenetic distance was
obtained via the weighted UniFrac algorithm. Tests were
performed using Pearson’s product-moment correlation coef-
ficient (r) with 999 permutations and a two-tailed test.
To compute specific correlations between observations of
bacterial taxa and colonic mucin-derived O-glycan
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Fig. 1. (A) The relative abundance of the taxa, as reported at the family level by Frese et al. 2017, of each fecal sample in this analysis. (B)
PCoA of the gut microbiome at the family level; control (CON) samples are shown as gray points, and EVC001-fed infant samples are
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structures, a Spearman’s q test was used. Raw correlation
statistics were tested for likelihood using Fisher’s Z trans-
formation and P-values corrected via Benjamini–Hochberg
false discovery rate (FDR) procedure.
Results and Discussion
Comparisons of the gut microbiome among a
subselected cohort
The gut microbiome of samples analyzed by mass
spectrometry from infants profiled by Frese et al. is
shown in Fig. 1A. Infants were fed 1.8 x 1010 CFU
per day of B. infantis EVC001 for 21 days from Day
7 to Day 29 postnatal. Infants fed EVC001 had
significantly high levels of Bifidobacterium and signifi-
cantly lower levels of Bacteroides than control
infants not fed B. infantis EVC001. Bacteroides was
the predominant mucolytic taxon identified in the
samples [23]. Notably, B. infantis fails to grow on
colonic mucin as a sole carbon source [15], and the
relative abundance of Bacteroidaceae was negatively
correlated with the abundance of Bifidobacteriaceae
(Spearman’s q = 0.65; P = 0.0029). Among the 19
samples profiled by nano-HPLC-Chip-TOF here, the
gut microbiome profiles for nine infants fed B. infan-
tis EVC001 were significantly different as tested by
PERMANOVA (R = 26.5, P = 0.001) from that of
the 10 control infants (Fig. 1B). Even when all Bifi-
dobacterium-matched reads were filtered from the
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samples, the residual microbial communities were
still significantly different according to treatment
group when compared by PERMANOVA (R = 13.8,
P = 0.001).
Fecal glycomics indicates differences among
release of colonic mucin-derived O-glycans from
glycoproteins in vivo
The total OS compositions of the samples were deter-
mined by the untargeted approach of nano-HPLC-
Chip-TOF. The compounds were characterized using
previously published libraries [21,24–26]. Among these
compositions, free HMOs and free colonic mucin-
derived O-glycans were found in the infant fecal gly-
come. The main focus of this study was to understand
the degradation of human colonic mucin glycans by
different gut microbiome profiles. This was determined
as the difference between a gut microbiome from
infants colonized with B. infantis EVC001 and micro-
biomes with a greater abundance of mucolytic taxa,
such as Bacteroidaceae. As target molecules, 1HexNAc-
1NeuAc, 1HexNAc-1Hex-NeuAc, 2H
exNAc-1NeuAc, 2HexNAc-1Hex-1Fuc, 2HexNAc-
1Hex-1NeuAc, 2HexNAc-1Hex-2Fuc, 3HexNAc-1Hex-
1Fuc, 2HexNAc-1Hex-1Fuc-1NeuAc, 2HexNAc-1Hex-
1Fuc-2NeuAc, 3HexNAc-1Hex-2NeuAc and 3Hex-
NAc-1Hex-2Fuc-1NeuAc were selected as typical
human colonic mucin glycans, as shown by Robbe
et al. [21]. The mass spectrometry monitoring these
structures showed that the number of total OS struc-
tures (including isomers and anomers) in samples from
control and EVC001-fed infants ranged from
67.4  19.81 and 360.44  102.52, respectively
(P < 0.001; Fig. 2A). Although the control samples
contained fewer total OS structures, the number of
freed human colonic mucin-derived O-glycans of the
total OS was significantly higher 25.4 (8.09), whereas
only 6.33 (2.24) structures were colonic mucin-derived
O-glycans in samples from EVC001-fed infants
(P < 0.001, Wilcoxon test; Fig. 2B). As a proportion,
the relative abundance of colonic mucin-derived O-gly-
cans was significantly higher in control samples than in
samples from EVC001-fed infants in terms of both the
number of structures (37.68%  3.14% and
1.78%  0.385%, respectively; Fig. 2C, P < 0.001,
Wilcoxon test) and their proportion of the total OS
profile (26.98%  8.48% and 1.68  1.12%, respectively;
Fig. 2D, P < 0.001, Wilcoxon test).
Associations between colonic mucin degradation
and the fecal microbiome
Overall, freed colonic mucin O-glycan composition dif-
fered significantly between EVC001-colonized and con-
trol infants when tested via PERMANOVA (R = 12.4,
P = 0.001; Fig. 3). However, to compare the composi-
tion of the gut microbiome with the abundance of
both total colonic mucin-derived O-glycans and the
specific structures monitored here, a Mantel test was
used to correlate these structures with the overall
microbiome composition. Broadly, the total colonic
mucin-derived O-glycan abundance was significantly
correlated with the microbiome composition (Mantel’s
R = 0.39, P = 0.01). Of these, only 1_0_0_1 (Mantel’s
R = 0.22, P = 0.05), 1_1_0_1 (Mantel’s R = 0.3, P =
0.027), 2_1_1_0 (Mantel’s R = 0.46, P = 0.003),
2_1_1_1 (Mantel’s R = 0.42, P = 0.003), 2_1_2_0
(Mantel’s R = 0.69, P = 0.001), 3_1_1_0 (Mantel’s
R = 0.35, P = 0.011), and 3_1_2_1 (Mantel’s R = 0.37,
P = 0.005) were significantly associated with specific
microbiome compositions.
To examine the interactions of the gut microbiome
and the colonic mucin-derived O-glycan species, a
Pearson correlation was calculated for all taxa and
structures in the samples, as well as the total abun-
dance and proportion of colonic mucin-derived O-gly-
can species (Table 1). Bifidobacteriaceae abundance
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Fig. 3. PCoA of colonic mucin-derived O-glycan composition
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(Con) samples are shown as gray points, and EVC001-fed infant
samples are shown as teal points. 63.3% of total variation was
explained in the first two principal components (PC1 and PC2).
PERMANOVA comparisons identified a significant difference
between the two groups, with respect to colonic mucin-derived O-
glycan composition (R = 12.4; P = 0.001).
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was significantly and negatively correlated with the
abundance of colonic mucin-derived O-glycans, as a
whole (Spearman’s q = 0.66, P = 0.04), whereas
Bacteroidaceae was significantly and positively corre-
lated with the abundance of 1_0_0_1, 2_1_1_1,
3_1_2_1, and 2_1_2_0 (Table 2). Interestingly, Enter-
obacteriaceae, who are unlikely to degrade mucus
themselves, were significantly correlated with the over-
all abundance of colonic mucin-derived O-glycans
(Spearman’s q = 0.061, P = 0.04) as well as 1_0_0_1
(Spearman’s q = 0.63, P = 0.03), and 2_1_2_0 (Spear-
man’s q = 0.71, P = 0.003). Similarly, Clostridiaceae
(Spearman’s q = 0.7, P = 0.01) and Planococcaceae
(Spearman’s q = 0.63, P = 0.03) were significantly
correlated with 2_1_1_0. While Pasteurellaceae were
significantly correlated with the overall abundance of
colonic mucin-derived O-glycans, they were not asso-
ciated with specific O-glycan species. Interestingly,
three of these colonic mucin-derived O-glycan species
(1_1_1_0, 3_1_1_0 and 3_1_2_1) were significantly
associated with microbiome compositions, but no
individual taxa were responsible for this association.
The broad associations between diminished abun-
dance, number, and proportion of colonic mucin-
Table 1. Colonic mucin-derived O-glycan structure, composition, mass, and volume in samples from the two treatment groups.
Glycan
code Composition
Neutral
mass
Log10 volume
control
[Mean (SD)]
Log10 volume
EVC001-fed [Mean (SD)]
Holm–Sidak adjusted
P value
1_0_0_1 1HexNAc-1NeuAc 512 7.19 (7.08) 5.44 (5.55) 0.010659
1_1_0_1 1HexNAc-1Hex-1NeuAc 675 5.96 (6.01) 4.06 (4.53) 0.09968
2_0_0_1 2HexNAc-1NeuAc 716 5.93 (6.16) 0 (0) 0.258702
2_1_1_0 2HexNAc-1Hex-1Fuc 735 6.17 (6.23) 0 (0) 0.09968
2_1_0_1 2HexNAc-1Hex-1NeuAc 878 5.9 (6.11) 5.5 (5.56) 0.502866
2_1_2_0 2HexNAc-1Hex-2Fuc 879 6.45 (5.95) 5.46 (5.51) 3.13E-06
3_1_1_0 3HexNAc-1Hex-1Fuc 936 6.43 (6.31) 5.32 (5.43) 0.015609
2_1_1_1 2HexNAc-1Hex-1Fuc-1NeuAc 1024 7.31 (7.01) 5.42 (5.54) 0.000189
2_1_1_2 2HexNAc-1Hex-1Fuc-2NeuAc 1315 7.08 (7.26) 6.71 (7.02) 0.502866
3_1_0_2 3HexNAc-1Hex-2NeuAc 1372 6.43 (6.52) 5.25 (5.4) 0.141386
3_1_2_1 3HexNAc-1Hex-2Fuc-1NeuAc 1373 7.52 (7.28) 5.77 (5.85) 0.000895
Table 2. Correlational analysis comparing microbiome composition (Mantel test) and specific bacterial families (Spearman’s q) with colonic
mucin-derived O-glycans.
Mucin-glycan Structures Mantel r Mantel P-value Bacterial family Spearman’s q P-value (FDR)
Total 0.39 0.01 Bifidobacteriaceae 0.66 0.04
Enterobacteriaceae 0.63 0.04
Pasteurellaceae 0.61 0.04
1_0_0_1 0.22 0.05 Bifidobacteriaceae 0.65 0.03
Enterobacteriaceae 0.63 0.03
Bacteroidaceae 0.63 0.03
1_1_0_1 0.3 0.027
2_0_0_1 0.03 0.826
2_1_0_1 0.07 0.590
2_1_1_0 0.46 0.003 Clostridiaceae 0.7 0.01
Planococcaceae 0.63 0.03
Bifidobacteriaceae 0.63 0.03
2_1_1_1 0.42 0.003 Bacteroidaceae 0.69 0.01
Bifidobacteriaceae 0.67 0.01
2_1_1_2 0.19 0.109
2_1_2_0 0.69 0.001 Bifidobacteriaceae 0.82 7.85E-05
Bacteroidaceae 0.72 0.003
Enterobacteriaceae 0.71 0.003
3_1_0_2 0.25 0.062
3_1_1_0 0.35 0.011
3_1_2_1 0.37 0.005
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derived O-glycans and colonization by B. infantis
EVC001 was reflected in the negative correlations
between the abundance of Bifidobacteriaceae and both
total colonic mucin-derived O-glycan abundance and
four of the mucin-derived O-glycan species monitored
here. Similarly, the abundance of a known mucin-
degrading family, Bacteroidaceae, was positively corre-
lated with the abundance of these same structures.
Many Bacteroides species allocate a large proportion
of their genome to harvesting polysaccharides, includ-
ing mucin [27], and the significant positive correlation
with colonic mucin-derived O-glycan concentrations
supports these previous findings, even though 16S
rRNA gene sequencing here does not confidently dis-
tinguish between OTUs at the species level. Many of
the genes associated with polysaccharide utilization
common to mucin-degrading Bacteroides are highly
active on mucin glycoproteins, including the O-glycan
cores found in human colonic mucin, as evidenced
here. Bacteroides can grow on mucin a sole carbon
source and have specific transcriptional responses to
incubation with mucin [13]. In particular, Bacteroides
broadly possess enzymes from glycosyl hydrolase (GH)
family GH 84, GH 85, GH 89, GH 101, and GH 129
that are active on mucin glycoproteins and may facili-
tate the release of these glycans from the mucin pro-
tein [13,27,28]. The release of these structures may
facilitate the growth of taxa which are potentially
pathogenic (e.g., Clostridiaceae and Enterobacteri-
aceae), and sialylated and fucosylated glycans derived
from host mucin have been shown to play a major role
in disease pathogenesis by Salmonella, Clostridium dif-
ficile, and cytotoxic Escherichia coli [9] and taxa that
act as reservoirs of virulence factors in the infant gut
[29].
Conclusion
The human gastrointestinal epithelium is protected by
a layer of mucus. Mucin, as a glycoprotein, is coated
with a wide variety of conjugated glycans that can
serve as a carbon source for mucolytic bacteria, and
their release may facilitate the growth of other taxa
such as Enterobacteriaceae and Clostridiaceae. Specifi-
cally, human colon mucins contain unique O-glycan
structures that can be utilized only by few mucolytic
taxa, and in breastfed infants, the predominant muco-
lytic taxon was Bacteroidaceae. These bacteria harbor
multiple GH-encoding genes that facilitate the libera-
tion of colonic mucin O-glycan from glycoproteins.
Our results show that gut microbiomes of infants colo-
nized by B. infantis have diminished mucin degrada-
tion, as evidenced by reduced abundance and diversity
of freed colonic mucin-derived O-glycans, as well as
the negative correlations between these and Bifidobac-
teriaceae. B. infantis is not able to cleave colonic
mucin-derived O-glycans, and their colonization is
associated with diminished populations of Bac-
teroidaceae [17]. Infants with a gut microbiome with
higher relative abundance of mucolytic taxa have
enhanced mucin degradation, and this may have long-
term health consequences, or increase their susceptibil-
ity to infection from taxa harboring virulence factors
via cross-feeding [6,9,29]. Further studies are required
to determine the specific negative effects of mucin
degradation, the role of these taxa in diminishing host
gut barrier function, and any functional consequences
to the host.
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